GSK ’s Candidate Shingles Vaccine Shows High Efficacy Against Shingles and its Complications in Adults Aged 70 Years and Over
14 September 2016 -- GSK (LSE/NYSE: GSK) today announced the publication of detailed results from a randomised phase III study (ZOE-70) of its investigational shingles vaccine, Shingrix, showing 90% efficacy in adults aged 70 years and older that is... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 14, 2016 Category: Pharmaceuticals Source Type: clinical trials
Immune Response to Shingles Vaccination
Condition: ShinglesIntervention: Drug: Zoster Vaccine LiveSponsors: University of Washington; Merck Sharp & Dohme Corp.Not yet recruiting - verified December 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 2, 2015 Category: Research Source Type: clinical trials
Study to Evaluate the Safety and Pharmacokinetics of Topically Applied 40% Lidocaine Gel Compared With Placebo in Subjects With Acute Herpes Zoster (Shingles) Pain
Condition: Acute-onset Herpes Zoster PainInterventions: Drug: CNTX-2022 (lidocaine gel, 40%); Drug: PlaceboSponsor: Centrexion TherapeuticsTerminated - verified February 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2015 Category: Research Source Type: clinical trials
